BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 8, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Synchron begins first-in-human trials of digital spinal cord in Australia

April 25, 2019
By Tamra Sami

Que Oncology launches phase II trials for hot flashes in breast cancer patients

April 24, 2019
By Tamra Sami
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
Read More

Que Oncology launches phase II trials for hot flashes in breast cancer patients

April 22, 2019
By Tamra Sami
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
Read More

Researchers step up treatment for diabetes with 3D-printed feet

April 19, 2019
By Tamra Sami

Australia's TGA updates risk management plan requirements for new drugs and biologics

April 17, 2019
By Tamra Sami
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
Read More

Australia's TGA updates risk management plan requirements for new drugs and biologics

April 15, 2019
By Tamra Sami
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
Read More

TGA says it won't give manufacturers more time to comply with new advertising regs

April 12, 2019
By Tamra Sami

Industry stakeholders laud TGA action plan to fast track Australian device reforms

April 10, 2019
By Tamra Sami

Singapore-headquartered Cerecin targets metabolic pathway for AD treatment

April 10, 2019
By Tamra Sami
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
Read More

Australian government commits AU$1B-plus to genomics, cancer

April 10, 2019
By Tamra Sami
PERTH, Australia – The Australian government's commitment of more than AU$1 billion (US$711 million) to support medical research in cancer and genomics sends the message to investors that the life sciences sector in Australia is sustainable, stakeholders said.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing